Unsafe
Not Aligned
Patient Risk:
High
Summary
Most extracted claims assert specific adverse reactions, causal relationships, and urgency/clinical interpretation that are not supported by the supplied FDA label sections. Only pregnancy/birth-defect and iPLEDGE-related claims are supported in the provided excerpts; adverse-reaction frequency and symptom-to-serious-diagnosis mappings are largely unsupported.
Category Scores
Accurate Statements
Claravis must not be used by patients who are or may become pregnant due to an extremely high risk of life-threatening birth defects if pregnancy occurs during treatment.
CONTRAINDICATIONS AND WARNINGS (pregnancy prohibition; extremely high risk of life-threatening birth defects)
Pregnancy prevention requirements are central to isotretinoin prescribing (iPLEDGE special restricted distribution program; prescriber/dispensing/patient enrollment requirements).
CONTRAINDICATIONS AND WARNINGS (Special Prescribing Requirements; iPLEDGE REMS; prescribers and pharmacies enrolled/activated; patients enrolled and meet requirements)
Pregnancy during isotretinoin treatment is associated with extremely high risk of severe, life-threatening fetal harm (life-threatening birth defects).
CONTRAINDICATIONS AND WARNINGS (extremely high risk that life-threatening birth defects will result if pregnancy occurs while taking Claravis)
Unsupported Statements
Claravis can cause side effects that commonly affect the skin and eyes.
Supplied label excerpts do not provide adverse-reaction details or frequency supporting 'commonly' for skin and eyes.
Common side effects include dry lips (cheilitis) and dry skin.
No supplied adverse-reaction listing includes cheilitis or dry skin.
Common side effects include dry eyes.
No supplied adverse-reaction content supports 'dry eyes' as a (common) adverse reaction.
Common side effects include nose dryness or nosebleeds.
No supplied adverse-reaction content supports nasal dryness or nosebleeds.
Common side effects include a rash.
No supplied adverse-reaction content supports rash as a common adverse reaction.
Common side effects include itching.
No supplied adverse-reaction content supports itching as a common adverse reaction.
Common side effects include temporary peeling of the skin.
No supplied adverse-reaction content supports skin peeling.
Claravis can cause severe allergic reactions, such as swelling of the face or throat and trouble breathing.
No supplied label excerpt supports this specific allergic reaction presentation.
Claravis can cause vision problems or severe eye pain.
No supplied adverse-reaction content supports these specific eye/vision symptom claims.
Claravis can cause severe headaches, dizziness, or changes in vision.
No supplied adverse-reaction content supports these symptoms as stated.
Severe headaches, dizziness, or changes in vision during isotretinoin treatment can be warning signs of increased pressure in the head.
No supplied label excerpt supports the symptom-to-increased-pressure linkage.
Claravis can cause severe abdominal pain.
No supplied adverse-reaction content supports severe abdominal pain.
Claravis can cause persistent vomiting.
No supplied adverse-reaction content supports persistent vomiting.
Claravis can cause black/tarry stools.
No supplied adverse-reaction content supports black/tarry stools.
Claravis can cause signs of liver problems, such as jaundice (yellowing of the skin or eyes).
No supplied label excerpt supports jaundice or liver-problem sign as an adverse reaction.
Claravis can cause severe mood or behavior changes.
Although the label excerpt mentions depression in a drug interaction section, the specific claim about 'severe mood or behavior changes' is not substantiated by the supplied text.
Isotretinoin reduces oil gland activity and changes how skin and mucous membranes behave.
Mechanistic claim not supported by the supplied label excerpts.
The dryness from isotretinoin commonly leads to dry eyes, lip irritation, and nosebleeds.
No supplied label excerpt supports causal 'commonly leads to' framing or these specific sequelae.
Patients taking isotretinoin are advised to seek urgent medical help for severe symptoms consistent with serious reactions.
No supplied label excerpt provides patient-directed 'seek urgent medical help' guidance as stated.
Contradictions
Important Omissions
Adverse reactions and/or monitoring guidance specific to skin/eye/serious neurologic, GI, hepatic, and psychiatric events (including whether they are common vs serious, and what specific clinical actions are recommended) is not provided in the supplied label excerpts, yet many extracted claims present these details as if they were label-supported.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Many extracted claims assert specific adverse reactions, frequencies ('commonly'), and symptom-to-serious-diagnosis/urgency guidance that are not supported by the supplied label excerpts. This can lead to miscommunication of expected side effects and appropriate responses.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Overconfident, highly specific adverse-reaction and causal/urgency statements are not supported by the supplied FDA label sections; only pregnancy/iPLEDGE-related claims are supported.
Suggested Improvement
Restrict claims to label-supported content from the provided excerpts. For adverse reactions, only state what is explicitly present in the label text provided; remove mechanistic, frequency ('common'), and symptom-to-specific-diagnosis/urgency mappings unless directly supported by the supplied label.